An outpatient endoscopic procedure can reduce the weight regain that often occurs after stopping medications such as Ozempic and Wegovy. Initial results from a randomized clinical trial show that coating the duodenal mucosa helped participants maintain most of the loss achieved with tirzepatide.
The research was presented at Digestive Disease Week 2026. Cerca 70% of people who stop these medications regain most of their weight within 18 months. The study tested whether renewing the lining of the small intestine offers a lasting solution without continued medication use.
Técnica renews duodenum lining
Duodenal mucosal resurfacing uses controlled heat to remove damaged tissue in the first portion of the small intestine. The process stimulates the growth of a new, healthier layer.
Médicos perform the procedure endoscopically. Ele lasts a short time and does not require prolonged hospitalization. Participantes report rapid recovery. Most resume normal activities within a day.
Dra. Shelby Sullivan, of Dartmouth Health Weight Center, leads the work. Ela highlighted the need for options for those discontinuing GLP-1 due to cost, side effects, or personal preference. The study offers initial evidence that the technique can reset metabolism.
Resultados from the initial group of 45 participants
Todos volunteers lost at least 15% of their body weight on tirzepatide before stopping the medication. On average, the reduction reached 18 kilos.
Seis Months after the discontinuation, the group that received the real procedure regained much less weight. Aqueles with more extensive resurfacing maintained over 80% of the loss. The control group, which underwent a sham procedure, recovered about twice as much.
The difference between the groups increased over the months. Quem went through the extensive treatment and only gained about 3 pounds. The benefits appear to strengthen over time rather than diminish.
- Pacientes with extensive resurfacing gained back around 3 kg in six months
- Simulated Grupo recovered approximately double this amount
- Greater Benefício observed with greater extent of the procedure
- Metabolic Recuperação kept some of the health gains
Segurança and recovery profile
Nenhuma serious complication related to the device or the act was recorded. Participants did not distinguish the real procedure from the simulated procedure by symptoms.
Recovery involves general anesthesia followed by minimal rest. Equipes doctors observe patients for a short period before discharge.
Sullivan observed that the procedure behaves in a dose-dependent manner. Quanto, the more extensive the application, the greater the effect on weight maintenance. Isso enhances biological targeting in the intestine.
Intestino slender and metabolic control
Dietas rich in fat and sugar alter the lining of the duodenum over time. Essa change affects hormone production and the way the body processes food.
Resurfacing seeks to restore the normal functioning of this region. The goal is to stabilize metabolism at a lower body weight even without the medication.
Pesquisadores relate the duodenum to several signals that regulate appetite and energy use. Mucosal renewal can correct accumulated changes.
Próximos steps of the REMAIN-1 study
The trial already has more than 300 fully recruited and randomized participants. Core cohort six-month data is expected early in Q4 2026.
The sponsoring company plans to submit an application for marketing authorization later that year. The procedure is still experimental.
Especialistas tracks long-term results to confirm durability and safety on a larger scale. The focus remains on maintaining benefits without continued use of GLP-1.
